Cited 17 times in
Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강창무 | - |
dc.contributor.author | 김창수 | - |
dc.contributor.author | 박지애 | - |
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 이우정 | - |
dc.contributor.author | 조성경 | - |
dc.contributor.author | 황호경 | - |
dc.date.accessioned | 2017-02-24T11:43:52Z | - |
dc.date.available | 2017-02-24T11:43:52Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/146843 | - |
dc.description.abstract | This study investigated the oncologic impact of loss of SMAD4 expression in resected left-sided pancreatic cancer and its correlation with tumor metabolism.From 2005 to 2011, the medical records of patients who underwent radical distal pancreatectomy for resectable pancreatic cancer were retrospectively reviewed. Formalin-fixed, paraffin embedded tissue from 32 patients was investigated. Clinicopathological characteristics, immunostaining of SMAD4, and positron emission tomography-based parameters were analyzed in relation to oncologic outcomes.Thirteen patients were women and 19 were men, with a mean age of 63 ± 9.4 years. Mean resected tumor size was 3.3 ± 1.5 cm. Ten patients (31.3%) showed loss of SMAD4 expression. No significant clinicopathological differences were noted according to SMAD4 expression (P > 0.05); however, patients with loss of SMAD4 showed significantly poorer disease-free survival (mean 57.4 months vs mean 17.6 months, P = 0.006). As a cut-off value, a SUVmax of 4.5 was found to be predictive of loss of SMAD4 with a sensitivity of 75% and a specificity of 84.6%. In logistic regression analysis, SUVmax>4.5 was found to infer a 16-fold higher risk for loss of SMAD4 in resected left-sided pancreatic cancers (Exp[β] = 16.5, P = 0.012, 95% confidence interval: 1.832-148.606).Loss of SMAD4 is associated with poor oncologic outcomes. SUVmax can predict loss of SMAD4 in resected left-sided pancreatic cancer. SUVmax may be a clinical biomarker for detecting loss of SMAD4 expression and predicting early systemic metastasis. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.relation.isPartOf | MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biomarkers, Tumor/genetics* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18 | - |
dc.subject.MESH | Gene Silencing* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multimodal Imaging | - |
dc.subject.MESH | Neoplasm Recurrence, Local/diagnosis* | - |
dc.subject.MESH | Neoplasm Recurrence, Local/genetics* | - |
dc.subject.MESH | Neoplasm Recurrence, Local/mortality | - |
dc.subject.MESH | Neoplasm Recurrence, Local/pathology | - |
dc.subject.MESH | Pancreas/diagnostic imaging | - |
dc.subject.MESH | Pancreas/pathology | - |
dc.subject.MESH | Pancreatectomy* | - |
dc.subject.MESH | Pancreatic Neoplasms/genetics* | - |
dc.subject.MESH | Pancreatic Neoplasms/mortality | - |
dc.subject.MESH | Pancreatic Neoplasms/pathology | - |
dc.subject.MESH | Pancreatic Neoplasms/surgery* | - |
dc.subject.MESH | Positron-Emission Tomography | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Smad4 Protein/genetics* | - |
dc.subject.MESH | Statistics as Topic | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Tomography, X-Ray Computed | - |
dc.title | Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Surgery | - |
dc.contributor.googleauthor | Chang Moo Kang | - |
dc.contributor.googleauthor | Ho Kyoung Hwang | - |
dc.contributor.googleauthor | Jiae Park | - |
dc.contributor.googleauthor | Changsoo Kim | - |
dc.contributor.googleauthor | Seong-Kyoung Cho | - |
dc.contributor.googleauthor | Mijin Yun | - |
dc.contributor.googleauthor | Woo Jung Lee | - |
dc.identifier.doi | 10.1097/MD.0000000000003452 | - |
dc.contributor.localId | A00088 | - |
dc.contributor.localId | A01042 | - |
dc.contributor.localId | A01689 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A02993 | - |
dc.contributor.localId | A04679 | - |
dc.contributor.localId | A04497 | - |
dc.relation.journalcode | J02214 | - |
dc.identifier.eissn | 1536-5964 | - |
dc.identifier.pmid | 27124039 | - |
dc.contributor.alternativeName | Kang, Chang Moo | - |
dc.contributor.alternativeName | Kim, Chang Soo | - |
dc.contributor.alternativeName | Park, Jiae | - |
dc.contributor.alternativeName | Yun, Mi Jin | - |
dc.contributor.alternativeName | Lee, Woo Jung | - |
dc.contributor.alternativeName | Cho, Seong-Kyung | - |
dc.contributor.alternativeName | Hwang, Ho Kyoung | - |
dc.contributor.affiliatedAuthor | Kang, Chang Moo | - |
dc.contributor.affiliatedAuthor | Kim, Chang Soo | - |
dc.contributor.affiliatedAuthor | Park, Jiae | - |
dc.contributor.affiliatedAuthor | Yun, Mi Jin | - |
dc.contributor.affiliatedAuthor | Lee, Woo Jung | - |
dc.contributor.affiliatedAuthor | Cho, Seong-Kyung | - |
dc.contributor.affiliatedAuthor | Hwang, Ho Kyoung | - |
dc.citation.volume | 95 | - |
dc.citation.number | 17 | - |
dc.citation.startPage | 3452 | - |
dc.identifier.bibliographicCitation | MEDICINE, Vol.95(17) : 3452, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 47938 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.